Research and Markets: Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/qshfb5/special_report) has announced the addition of Decision Resources, Inc's new report "Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis" to their offering.

Current treatment for the symptoms associated with multiple sclerosis (MS) is dominated by generic, off-label therapies with mixed efficacy or modest clinical trial evidence. Acorda Therapeutics' Ampyra, Allergan's Botox, and Avanir Pharmaceuticals' Nuedexta make up the crop of new niche agents in the United States indicated specifically for the treatment of individual symptoms that commonly occur in patients with this chronic disease. Although these agents are available, demand for additional therapies that offer relief of disabling MS-related symptoms remains high, and agents that can demonstrate clinically meaningful efficacy have the potential to command sizable prices and enjoy modest uptake in discrete, and in some cases sizable, patient subgroups in this lucrative market.

Key Topics Covered:

- Executive Summary

- Strategic Considerations

- Stakeholder Implications

- Introduction

- Overview of Multiple Sclerosis

- Current Therapies and Patient Estimates for MS-Associated Symptoms

View post:
Research and Markets: Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis